Search Results for "Grifols Biomat Employee Portal"

19:12 EDT 24th October 2014 | BioPortfolio

Original Source: Grifols, Inc.

Currently, we supply plasma products, diagnostic reagents, automated analyzers and dosing machines.In 1998, Grifols established a joint venture with a US diagnostic company, Quest International. Then, in 2000 in order to prepare for an even greater presence in the USA with its plasma products, Grifols founded Grifols USA.Grifols acquired SeraCare’s network of 45 plasmapheresis centers in 2002, thereby vertically integrating the company and guaranteeing its supply of plasma. A year later, Grifols acquired ...

Matching Channels

Matching News

Grifols, Governor McCrory, And Dignitaries Open State-Of-The-Art Facility In Clayton, NC On June 17

Grifols North Fractionation Facility will be Home to 200 Employees and Help Advance Treatment of Rare and Life-Threatening Diseases WHAT:Grifols, along with North Carolina Governor Pat McCrory, el...

Grifols gets CE mark for hepatitis E detection test

Grifols has earned the CE mark in Europe for the Procleix HEV test, which it developed with Hologic.  -More- 

Spain's Grifols Q1 net profit grows 33 percent

May 6 (Reuters) - Spanish pharmaceutical company Grifols , the world's third-largest blood products maker, posted a 32.9 percent rise in first-quarter net profit on Tuesday to 121 million euros ($168 ...

Spain's Grifols H1 adjusted profit up 25 pct, misses fcasts

MADRID, July 31 (Reuters) - Spanish healthcare firm Grifols said first half adjusted net profit rose 25 percent on Thursday, slightly below analysts' expectations in a Reuters poll and boosted by the ...

Grifols introduces 2000 FVIII IU ALPHANATE assay

Spanish producer of plasma-derived medicines Grifols has launched a 2000 IU/vial assay size for ALPHANATE (antihemophilic factor/von Willebrand factor complex [human]).

REFILE-Spain's Grifols H1 adjusted profit up 25 pct, misses fcasts

MADRID, July 31 (Reuters) - Spanish healthcare firm Grifols said first half adjusted net profit rose 25 percent on Thursday, slightly below analysts' expectations in a Reuters poll and boosted by the ...

World's First Breath-Test for Portal Hypertension

Portal hypertension is the most common complication of cirrhosis, accounting for significant morbidity and mortalityRead more about World's First Breath-Test for Portal HypertensionComments

Waldorf Risk Solutions Releases New Risk Management Portal

Huntington, New York (PRWEB) September 21, 2014 Waldorf Risk Solutions, LLC announces the release of their Risk Management Portal designed for Diocesan risks. The portal features four custom cloud ...

Matching PubMed Articles

Nitrate Removal in Shallow, Open-Water Treatment Wetlands.

The diffuse biomat formed on the bottom of shallow, open-water unit process wetland cells contains suboxic zones that provide conditions conducive to NO3(-) removal via microbial denitrification, as w...

Absent portal vein bifurcation: a rare variant and its clinical significance.

Portal vein branching anomaly occurs due to aberration of normal anastomotic patterns and involution of vitelline veins during development of portal vein. Anatomical knowledge of portal vein and its b...

Shift Work and Employee Fatigue: Implications for Occupational Health Nursing.

Long work hours and irregular shifts are part of the nation's 24-hour society and contribute to employee fatigue. Factors affecting employee fatigue are circadian rhythm, sleep quality and quantity, i...

Portal hypertension: A critical appraisal of shunt procedures with emphasis on distal splenorenal shunt in children.

Extrahepatic portal venous obstruction (EHPVO) is the most common cause of pediatric portal hypertension. We analyzed the investigative protocol and results of portosystemic shunts in this group of pa...

Portal inflow preservation during portal diversion in small-for-size syndrome.

To investigate the impact of portal inflow on liver remnants in a stable pig model of small-for-size syndrome.

Search Whole site using Google

Loading
Search BioPortfolio:
Loading
Advertisement
Advertisement
Advertisement Advertisement